XML 57 R40.htm IDEA: XBRL DOCUMENT
v3.21.2

Variable Interest Entity - Additional Information (Detail) | Jun. 30, 2021
--- | ---
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member] | Beijing Falikang Pharmaceutical Co Ltd | FibroGen Beijing [Member] | AstraZenecaAB [Member] |
Acquisition And Variable Interest Entity [Line Items] |
Percentage of outstanding shares acquired | 51.10%

X
- Definition Acquisition and variable interest entity line items. + References No definition available. + Details
Name: | fgen_AcquisitionAndVariableInterestEntityLineItems
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of voting equity interests acquired at the acquisition date in the business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=fgen_BeijingKangdaYongfuPharmaceuticalCoLTDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=fgen_BeijingFalikangPharmaceuticalCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=fgen_FibroGenBeijingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=fgen_AstraZenecaABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |